Elecsys Anti-HBs / Elecsys HBs II
FDA premarket approval P190034/S009 · decided 2024-10-03
Approval details
- PMA number
- P190034
- Supplement
- S009
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- Elecsys Anti-HBs / Elecsys HBs II
- Generic name
- Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
- Applicant
- Roche Diagnostics
- Date received
- 2024-09-10
- Decision date
- 2024-10-03
- Days to decision
- 23 days
- Decision code
- OK30
- Product code
- LOM
- Advisory committee
- Microbiology
- Expedited review
- No
- Location
- Indianapolis, IN
- Statement
- to add another location for a process within the same establishment
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| cobas pulse blood glucose monitoring system (K252323) | Roche Diagnostics | 2026-06-12 |
| Elecsys Anti-SARS-CoV-2 S (K252280) | Roche Diagnostics | 2026-04-13 |
| Elecsys Anti-HBc IgM (K260049) | Roche Diagnostics | 2026-04-07 |
| Elecsys Anti-HBc II (K260046) | Roche Diagnostics | 2026-04-07 |
| Elecsys Anti-HAV IgM (K260048) | Roche Diagnostics | 2026-04-07 |
| Tina-quant Cardiac high sensitivity CRP III (K260026) | Roche Diagnostics | 2026-04-02 |
| Glucose HK Gen.3; ONLINE DAT Methadone II; cobas pro integrated solutions (K253490) | Roche Diagnostics | 2026-02-12 |
| ISE indirect K for Gen.2; ISE indirect Na for Gen.2; ISE indirect Cl for Gen.2; cobas pro integrated solutions (K253491) | Roche Diagnostics | 2026-02-12 |